CWA
GBT

Clarus Wealth Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Clarus Wealth Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-476
Closed -$25K – 591
2019
Q2 		$25K Hold
476
– – 0.02% 345
2019
Q1 		$25K Hold
476
– – 0.02% 387
2018
Q4 		$20K Buy
476
+238
+100% +$8.92K 0.03% 407
2018
Q3 		$9K Buy
+238
New +$10.5K 0.01% 560

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Clarus Wealth Advisors's GBT Position: Q3 2019 in Review

Clarus Wealth Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2019, closing a stake of 476 shares — an estimated $25K sold.

Clarus Wealth Advisors first reported a position in GBT in Q3 2018 and held it in 4 quarters. The position peaked at $25K in Q2 2019. 208 funds tracked by Wall St. Rank hold GBT as of Q3 2019.

  • Clarus Wealth Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Clarus Wealth Advisors sold 476 Global Blood Therapeutics, Inc. shares in Q3 2019, an estimated $25K.
  • Clarus Wealth Advisors first reported a position in Global Blood Therapeutics, Inc. in Q3 2018 and held it in 4 quarters.
  • Clarus Wealth Advisors's Global Blood Therapeutics, Inc. position peaked at $25K in Q2 2019.
  • 208 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2019.

Based on Clarus Wealth Advisors's 13F filing for Q3 2019, filed 11 Oct 2019.